Salman Hussain is a panelist during the conference. He is discussing patient-focused drug development, bringing a precision medicine approach to alopecia areata, and the latest patient reported outcomes tools and biomarker studies. The roundtable discussion includes representatives from several pharmaceutical companies, a couple physicians/researchers, and patient advocacy group members.
For more inforamtion on this event, click here.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...